SLC25A32

Summary

SLC25A32 (solute carrier family 25 member 32, HGNC:29683) is a protein-coding gene on chromosome 8q22.3, encoding Solute carrier family 25 member 32 (Q9H2D1). Facilitates flavin adenine dinucleotide (FAD) translocation across the mitochondrial inner membrane into the mitochondrial matrix where it acts as a redox cofactor to assist flavoenzyme activities in fundamental metabolic processes including fatty acid beta-oxidation, amino acid….

This gene encodes a member of the P(I/L)W subfamily of mitochondrial carrier family transport proteins. The encoded protein transports folate across the inner mitochondrial membrane. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 81034 — RefSeq curated summary.

At a glance

• Gene–disease (curated): exercise intolerance, riboflavin-responsive (Strong, GenCC)
• Clinical variants (ClinVar): 260 total
• Phenotypes (HPO): 3
• MANE Select transcript: NM_030780

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29683
Approved symbol	SLC25A32
Name	solute carrier family 25 member 32
Location	8q22.3
Locus type	gene with protein product
Status	Approved
Aliases	MFTC
Ensembl gene	ENSG00000164933
Ensembl biotype	protein_coding
OMIM	138480
Entrez	81034

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 nonsense_mediated_decay, 2 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000297578, ENST00000521645, ENST00000523256, ENST00000523701, ENST00000523866, ENST00000707124

RefSeq mRNA: 1 — MANE Select: NM_030780 NM_030780

CCDS: CCDS6300

Canonical transcript exons

ENST00000297578 — 7 exons

Exon	Start	End
ENSE00001088754	103404776	103404861
ENSE00002094549	103414784	103415107
ENSE00003472032	103401941	103402054
ENSE00003477724	103403164	103403324
ENSE00003496913	103407634	103407784
ENSE00003618359	103401516	103401661
ENSE00003637630	103398638	103400546

Expression profiles

Bgee: expression breadth ubiquitous, 135 present calls, max score 90.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 40.2012 / max 224.4358, expressed in 1822 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
94334	36.6500	1820
94333	2.5770	1349
94335	0.4970	255
94336	0.4771	247

Top tissues by expression

135 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	90.19	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.95	gold quality
lymph node	UBERON:0000029	87.89	gold quality
stromal cell of endometrium	CL:0002255	87.60	gold quality
islet of Langerhans	UBERON:0000006	87.54	gold quality
smooth muscle tissue	UBERON:0001135	87.49	gold quality
subcutaneous adipose tissue	UBERON:0002190	87.04	gold quality
adipose tissue	UBERON:0001013	86.99	gold quality
omental fat pad	UBERON:0010414	86.92	gold quality
popliteal artery	UBERON:0002250	86.66	gold quality
tibial artery	UBERON:0007610	86.66	gold quality
vermiform appendix	UBERON:0001154	86.59	gold quality
left uterine tube	UBERON:0001303	86.21	gold quality
ascending aorta	UBERON:0001496	85.92	gold quality
thoracic aorta	UBERON:0001515	85.92	gold quality
left coronary artery	UBERON:0001626	85.88	gold quality
endometrium	UBERON:0001295	85.51	gold quality
left ovary	UBERON:0002119	85.24	gold quality
right ovary	UBERON:0002118	85.17	gold quality
mammary gland	UBERON:0001911	85.16	gold quality
thoracic mammary gland	UBERON:0005200	85.16	gold quality
ovary	UBERON:0000992	85.01	gold quality
descending thoracic aorta	UBERON:0002345	85.01	gold quality
endocervix	UBERON:0000458	85.00	gold quality
body of uterus	UBERON:0009853	84.89	gold quality
corpus callosum	UBERON:0002336	84.66	gold quality
right coronary artery	UBERON:0001625	84.61	gold quality
gall bladder	UBERON:0002110	84.31	gold quality
superior frontal gyrus	UBERON:0002661	84.29	gold quality
ectocervix	UBERON:0012249	84.19	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.09
E-CURD-10	no	231.79

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

117 targeting SLC25A32, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-551B-5P	99.96	71.28	3493

Literature-anchored findings (GeneRIF, showing 8)

• Patient with SLC25A32 deficiency was able to have a successful pregnancy after fertilization in vitro. (PMID:19362304)
• identified residues in the walls and at the base of the transport cavity that are involved in substrate recognition by the MFT (PMID:21768094)
• Compares and contrasts all the known human SLC25A* genes and includes functional information. (PMID:23266187)
• SLC25A32 gene polymorphism could be a risk factor for lower folate concentration and future fracture. (PMID:24354357)
• A novel SLC25A32 homozygous variant is associated with severe neuromuscular phenotype. (PMID:28443623)
• These data demonstrate that the loss of functional Slc25a32 results in cranial neural tube defects (NTDs) in mice and has also been observed in a human NTD patient. (PMID:29666258)
• Hypoketotic hypoglycemia without neuromuscular complications in patients with SLC25A32 deficiency. (PMID:34764427)
• SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway. (PMID:37365560)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc25a32b	ENSDARG00000026835
danio_rerio	slc25a32a	ENSDARG00000089791
mus_musculus	Slc25a32	ENSMUSG00000022299
rattus_norvegicus	Slc25a32	ENSRNOG00000004403
drosophila_melanogaster	CG8026	FBGN0033391
caenorhabditis_elegans		WBGENE00010459

Paralogs (49): SLC25A13 (ENSG00000004864), SLC25A5 (ENSG00000005022), SLC25A39 (ENSG00000013306), SLC25A40 (ENSG00000075303), SLC25A3 (ENSG00000075415), SLC25A43 (ENSG00000077713), SLC25A24 (ENSG00000085491), SLC25A1 (ENSG00000100075), SLC25A17 (ENSG00000100372), SLC25A14 (ENSG00000102078), SLC25A15 (ENSG00000102743), SLC25A11 (ENSG00000108528), UCP1 (ENSG00000109424), SLC25A36 (ENSG00000114120), SLC25A12 (ENSG00000115840), SLC25A2 (ENSG00000120329), SLC25A51 (ENSG00000122696), SLC25A16 (ENSG00000122912), SLC25A35 (ENSG00000125434), SLC25A19 (ENSG00000125454), SLC25A23 (ENSG00000125648), SLC25A47 (ENSG00000140107), SLC25A52 (ENSG00000141437), SLC25A38 (ENSG00000144659), SLC25A26 (ENSG00000144741), SLC25A48 (ENSG00000145832), SLC25A37 (ENSG00000147454), SLC25A25 (ENSG00000148339), SLC25A31 (ENSG00000151475), SLC25A4 (ENSG00000151729), SLC25A27 (ENSG00000153291), SLC25A28 (ENSG00000155287), SLC25A44 (ENSG00000160785), SLC25A45 (ENSG00000162241), SLC25A34 (ENSG00000162461), SLC25A6 (ENSG00000169100), SLC25A33 (ENSG00000171612), SLC25A30 (ENSG00000174032), UCP3 (ENSG00000175564), UCP2 (ENSG00000175567)

Protein

Protein identifiers

Solute carrier family 25 member 32 — Q9H2D1 (reviewed: Q9H2D1)

Alternative names: Mitochondrial FAD transporter

All UniProt accessions (5): A0A9L9PY70, E5RFL3, E5RGK5, E5RGT9, Q9H2D1

UniProt curated annotations — full annotation on UniProt →

Function. Facilitates flavin adenine dinucleotide (FAD) translocation across the mitochondrial inner membrane into the mitochondrial matrix where it acts as a redox cofactor to assist flavoenzyme activities in fundamental metabolic processes including fatty acid beta-oxidation, amino acid and choline metabolism as well as mitochondrial electron transportation. In particular, provides FAD to DLD dehydrogenase of the glycine cleavage system, part of mitochondrial one-carbon metabolic pathway involved in neural tube closure in early embryogenesis.

Subcellular location. Mitochondrion inner membrane.

Tissue specificity. Ubiquitous.

Disease relevance. Exercise intolerance, riboflavin-responsive (RREI) [MIM:616839] A riboflavin-responsive form of exercise intolerance, a condition characterized by failure to maintain an expected level of force during sustained or repeated muscle contraction, resulting in an overwhelming sense of tiredness, lack of energy and feeling of exhaustion. RREI transmission pattern is consistent with autosomal recessive inheritance. The disease is caused by variants affecting the gene represented in this entry. Neural tube defects (NTD) [MIM:182940] Congenital malformations of the central nervous system and adjacent structures related to defective neural tube closure during the first trimester of pregnancy. Failure of neural tube closure can occur at any level of the embryonic axis. Common NTD forms include anencephaly, myelomeningocele and spina bifida, which result from the failure of fusion in the cranial and spinal region of the neural tube. NTDs have a multifactorial etiology encompassing both genetic and environmental components. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Similarity. Belongs to the mitochondrial carrier (TC 2.A.29) family.

RefSeq proteins (1): NP_110407* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002067	MCP	Family
IPR018108	MCP_transmembrane	Repeat
IPR023395	MCP_dom_sf	Homologous_superfamily
IPR044712	SLC25A32-like	Family

Pfam: PF00153

Catalyzed reactions (Rhea), 1 shown:

• FAD(in) = FAD(out) (RHEA:76535)

UniProt features (20 total): sequence variant 9, transmembrane region 6, repeat 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H2D1-F1	85.58	0.54

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-196757	Metabolism of folate and pterines
R-HSA-1430728	Metabolism
R-HSA-196849	Metabolism of water-soluble vitamins and cofactors
R-HSA-196854	Metabolism of vitamins and cofactors

MSigDB gene sets: 183 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GSE45365_NK_CELL_VS_BCELL_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_MODIFIED_AMINO_ACID_TRANSPORT, GOBP_NUCLEOTIDE_TRANSPORT, GOBP_DICARBOXYLIC_ACID_METABOLIC_PROCESS, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_ORGANIC_ACID_TRANSPORT, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, WEI_MYCN_TARGETS_WITH_E_BOX, ONKEN_UVEAL_MELANOMA_UP, MODULE_239, GOBP_PTERIDINE_CONTAINING_COMPOUND_METABOLIC_PROCESS, MYCMAX_01

GO Biological Process (8): folic acid metabolic process (GO:0046655), transmembrane transport (GO:0055085), mitochondrial FAD transmembrane transport (GO:1990548), nucleotide transport (GO:0006862), obsolete organic anion transport (GO:0015711), folic acid transport (GO:0015884), nucleotide transmembrane transport (GO:1901679), mitochondrial transmembrane transport (GO:1990542)

GO Molecular Function (3): folic acid transmembrane transporter activity (GO:0008517), FAD transmembrane transporter activity (GO:0015230), nucleotide transmembrane transporter activity (GO:0015215)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Metabolism of water-soluble vitamins and cofactors	1
Metabolism of vitamins and cofactors	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
FAD transmembrane transport	2
transmembrane transport	2
folic acid-containing compound metabolic process	1
dicarboxylic acid metabolic process	1
transport	1
cellular process	1
organophosphate ester transport	1
nucleobase-containing compound transport	1
dicarboxylic acid transport	1
vitamin transport	1
modified amino acid transport	1
nucleotide transport	1
mitochondrial transport	1
dicarboxylic acid transmembrane transporter activity	1
folic acid transport	1
modified amino acid transmembrane transporter activity	1
vitamin transmembrane transporter activity	1
nucleotide transmembrane transporter activity	1
organophosphate ester transmembrane transporter activity	1
nucleobase-containing compound transmembrane transporter activity	1
nucleotide transmembrane transport	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

810 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC25A32	MTCH1	Q9NZJ7	772
SLC25A32	FLAD1	Q8NFF5	761
SLC25A32	MTHFD1L	Q6UB35	676
SLC25A32	ETFDH	Q16134	643
SLC25A32	SLC25A51	Q9H1U9	637
SLC25A32	SLC52A1	Q9NWF4	637
SLC25A32	SLC25A52	Q3SY17	632
SLC25A32	SLC25A53	Q5H9E4	605
SLC25A32	GLDC	P23378	595
SLC25A32	SLC52A2	Q9HAB3	595
SLC25A32	SLC52A3	Q9NQ40	592
SLC25A32	RFK	Q969G6	575
SLC25A32	MTHFD2L	Q9H903	570
SLC25A32	MTHFD1	P11586	550
SLC25A32	SLC46A1	Q96NT5	530

IntAct

13 interactions, top by confidence:

A	B	Type	Score
IMPDH1	BCAT2	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
SLC25A32	NEDD8-MDP1	psi-mi:“MI:0914”(association)	0.350
SLC25A32	AKR1A1	psi-mi:“MI:0914”(association)	0.350
IMPDH1	MGST3	psi-mi:“MI:0914”(association)	0.350
SLC25A32	CRYAB	psi-mi:“MI:0914”(association)	0.350
AURKB	VWA8	psi-mi:“MI:0914”(association)	0.350
DNAJB2		psi-mi:“MI:0914”(association)	0.350
GSDME	DDX39A	psi-mi:“MI:0914”(association)	0.350
PIM1	IDH3B	psi-mi:“MI:0914”(association)	0.350
SLC18A2	MGST3	psi-mi:“MI:0914”(association)	0.350
SLC25A32	CS	psi-mi:“MI:0914”(association)	0.350

BioGRID (90): PLS1 (Affinity Capture-MS), NEDD8-MDP1 (Affinity Capture-MS), PMVK (Affinity Capture-MS), LASP1 (Affinity Capture-MS), CCDC25 (Affinity Capture-MS), UBE2T (Affinity Capture-MS), PICALM (Affinity Capture-MS), NIPSNAP3A (Affinity Capture-MS), CTH (Affinity Capture-MS), TCEA1 (Affinity Capture-MS), DENR (Affinity Capture-MS), PROSC (Affinity Capture-MS), CBFB (Affinity Capture-MS), SLC25A32 (Co-fractionation), SLC25A32 (Co-fractionation)

ESM2 similar proteins: A0A0G2K5L2, A0JN87, G3XP90, G3YAF3, O22261, O77792, O95847, O97562, P55851, P55916, P56500, P70406, Q08DK4, Q1LZB3, Q29RM1, Q3SZI5, Q3TZX3, Q4V9P0, Q505J6, Q5IS35, Q5NVC1, Q5R5A8, Q5RD81, Q5RFB7, Q5ZKP7, Q641C8, Q6DG32, Q6IZB5, Q6P036, Q7K566, Q8BMG8, Q8BZ09, Q922G0, Q95J75, Q96CQ1, Q99JD3, Q9BQT8, Q9BSK2, Q9C5M0, Q9D6D0

Diamond homologs: A0A1D6N272, A1DI57, A2A3V2, A2ASZ8, A2CEQ0, A5PJZ1, B0G159, B4F8I5, B4FIJ0, B8ZHC9, F1LX07, F4HW79, F4JU70, K7VYZ9, O04619, O18757, O65023, O75746, O81845, O94502, O97649, P04710, P05141, P0C546, P0CI40, P12235, P12857, P16260, P16261, P25083, P29518, P31167, P31691, P40941, P48962, P55916, Q01888, Q05AQ3, Q0II44, Q0P483

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

260 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	127
Likely benign	81
Benign	33

Top pathogenic / likely-pathogenic (0)

SpliceAI

940 predictions. Top by Δscore:

Variant	Effect	Δscore
8:103401934:ATCTT:A	donor_loss	1.0000
8:103401937:TTACC:T	donor_loss	1.0000
8:103401939:A:AC	donor_gain	1.0000
8:103401939:A:C	donor_loss	1.0000
8:103401940:C:CC	donor_gain	1.0000
8:103401940:CCAA:C	donor_gain	1.0000
8:103401943:A:AC	donor_gain	1.0000
8:103401944:C:CC	donor_gain	1.0000
8:103402050:AATCC:A	acceptor_gain	1.0000
8:103402052:TCC:T	acceptor_gain	1.0000
8:103402053:CC:C	acceptor_gain	1.0000
8:103402053:CCC:C	acceptor_gain	1.0000
8:103402054:CC:C	acceptor_gain	1.0000
8:103403221:T:A	donor_gain	1.0000
8:103404770:CCTTA:C	donor_loss	1.0000
8:103404771:CTT:C	donor_loss	1.0000
8:103404772:TTA:T	donor_loss	1.0000
8:103404773:TA:T	donor_loss	1.0000
8:103404774:ACCA:A	donor_loss	1.0000
8:103404775:CCAG:C	donor_gain	1.0000
8:103404857:TGTAA:T	acceptor_gain	1.0000
8:103404859:TAA:T	acceptor_gain	1.0000
8:103404862:C:CC	acceptor_gain	1.0000
8:103407632:A:AC	donor_gain	1.0000
8:103407633:C:CC	donor_gain	1.0000
8:103407688:C:CA	donor_gain	1.0000
8:103407781:CTCA:C	acceptor_gain	1.0000
8:103407782:TCA:T	acceptor_gain	1.0000
8:103407783:CA:C	acceptor_gain	1.0000
8:103407783:CAC:C	acceptor_gain	1.0000

AlphaMissense

2017 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:103400518:C:G	G281R	0.999
8:103400518:C:T	G281R	0.999
8:103401573:A:G	L252P	0.999
8:103402053:C:T	G185E	0.999
8:103402054:C:G	G185R	0.999
8:103402054:C:T	G185R	0.999
8:103403281:T:A	K145N	0.999
8:103403281:T:G	K145N	0.999
8:103403282:T:A	K145I	0.999
8:103403299:G:C	N139K	0.999
8:103403299:G:T	N139K	0.999
8:103400479:A:G	C294R	0.998
8:103400517:C:T	G281E	0.998
8:103401576:C:G	R251P	0.998
8:103401615:G:T	A238D	0.998
8:103402008:A:G	F200S	0.998
8:103403276:C:G	R147P	0.998
8:103404779:C:G	A130P	0.998
8:103404787:G:T	A127D	0.998
8:103407688:C:T	G84E	0.998
8:103407689:C:G	G84R	0.998
8:103407689:C:T	G84R	0.998
8:103401569:C:A	Q253H	0.997
8:103401569:C:G	Q253H	0.997
8:103401577:G:T	R251S	0.997
8:103401597:G:T	P244Q	0.997
8:103403273:A:G	L148P	0.997
8:103403292:A:G	W142R	0.997
8:103403292:A:T	W142R	0.997
8:103404778:G:T	A130D	0.997

dbSNP variants (sampled 300 via entrez): RS1000408848 (8:103406248 T>C), RS1000422463 (8:103413688 GT>G,GTT), RS1000526592 (8:103399467 A>T), RS1000782927 (8:103412465 T>C), RS1000802655 (8:103402965 T>C), RS1001287819 (8:103412224 T>C), RS1001474206 (8:103400115 A>G), RS1001526432 (8:103400314 G>A,T), RS1002090170 (8:103412335 G>A), RS1002130053 (8:103406739 T>A), RS1002291817 (8:103400132 T>C), RS1002438128 (8:103406291 C>T), RS1002733936 (8:103407974 A>G,T), RS1002755886 (8:103409594 C>T), RS1002811824 (8:103409852 G>A)

Disease associations

OMIM: gene MIM:138480 | disease phenotypes: MIM:616839

GenCC curated gene-disease

Disease	Classification	Inheritance
exercise intolerance, riboflavin-responsive	Strong	Autosomal recessive

Mondo (2): prostate cancer (MONDO:0008315), exercise intolerance, riboflavin-responsive (MONDO:0014795)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

3 total (3 of 3 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0003200	Ragged-red muscle fibers
HP:0003546	Exercise intolerance

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC25 mitochondrial vitamin and co-factor carriers subfamily

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, decreases methylation	3
Air Pollutants	affects cotreatment, decreases expression, increases abundance	2
Estradiol	increases expression	2
Cyclosporine	increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
alpha-pinene	decreases expression, increases abundance, affects cotreatment	1
beta-lapachone	decreases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
jinfukang	affects cotreatment, decreases expression	1
Valsartan	decreases reaction, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Acetaminophen	decreases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Dexamethasone	increases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Methyl Methanesulfonate	decreases expression	1
Ozone	decreases expression, increases abundance, affects cotreatment	1
Plant Extracts	increases expression, affects cotreatment	1
Smoke	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Dronabinol	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1

Cellosaurus cell lines

4 cell lines: 3 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3H7	Abcam HEK293T SLC25A32 KO	Transformed cell line	Female
CVCL_D4JV	HCT116-SLC25A32-KO-c1	Cancer cell line	Male
CVCL_D4JW	HCT116-SLC25A32-KO-c5	Cancer cell line	Male
CVCL_TM33	HAP1 SLC25A32 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer